Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
pharmaphorum11h
Gilead, MSD say HIV combo could be weekly, oral HIV drug
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Hosted on MSN1d
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
News243h
Talks have started to get the twice-yearly anti-HIV jab registered in SA
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
AlphaGalileo4h
Success of long-lasting HIV drug hinges on pricing
Six-monthly HIV drug, lenacapavir, reduced HIV incidence by 96 per cent in trial. Affordability and supply remain key hurdles for rollout.
2minutemedicine.com6d
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
The American Journal of Managed Care11d
Lenacapavir Highly Effective in Preventing HIV
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
BMJ7d
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...